Jay R. Luly

2017

In 2017, Jay R. Luly earned a total compensation of $4.3M as President and Chief Executive Officer at Enanta Pharmaceuticals, a 24% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$345,648
Option Awards$2,055,720
Salary$581,203
Stock Awards$1,279,980
Other$18,551
Total$4,281,102

Luly received $2.1M in option awards, accounting for 48% of the total pay in 2017.

Luly also received $345.6K in non-equity incentive plan, $581.2K in salary, $1.3M in stock awards and $18.6K in other compensation.

Rankings

In 2017, Jay R. Luly's compensation ranked 2,341st out of 14,666 executives tracked by ExecPay. In other words, Luly earned more than 84.0% of executives.

ClassificationRankingPercentile
All
2,341
out of 14,666
84th
Division
Manufacturing
822
out of 5,770
86th
Major group
Chemicals And Allied Products
216
out of 2,074
90th
Industry group
Drugs
165
out of 1,730
91st
Industry
Pharmaceutical Preparations
130
out of 1,329
90th
Source: SEC filing on January 19, 2018.

Luly's colleagues

We found four more compensation records of executives who worked with Jay R. Luly at Enanta Pharmaceuticals in 2017.

2017

Yat Or

Enanta Pharmaceuticals

Chief Scientific Officer

2017

Nathalie Adda

Enanta Pharmaceuticals

Chief Medical Officer

2017

Paul Mellett

Enanta Pharmaceuticals

Chief Financial Officer

2017

Nathaniel Gardiner

Enanta Pharmaceuticals

General Counsel

News

You may also like